Patient derived T cells activated ex vivo with CD3/CD28 beads show superior expansion. Therefore, CD3/CD28 beads have huge potential to be used in the clinic for immunotherapy applications. Two protocols were devised to evaluate if the expression of third-generation human epidermal growth factor receptor 2 chimeric antigen receptor (CAR) can be improved on human T cells activated with CD3/CD28 beads. In protocol 1, unconcentrated human epidermal growth factor receptor 2 CAR retroviral supernatants were used, and in protocol 2, concentrated virus was used. The results demonstrate that compared to unconcentrated viral supernatants, transduction with the concentrated virus improved the infection rate of bead activated CD4 T cells from ∼40% to ∼70%, and the fluorescent intensity values improved from ∼12,000 to ∼28,000 mean fluorescence intensity units. These results demonstrate the utility of these protocols for CAR immunotherapies.
Get full access to this article
View all access options for this article.
References
1.
YunCO, NolanKF, BeechamEJ, et al.Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia, 2000; 2:449–459.
2.
BeechamEJ, Ortiz-PujolsS, JunghansRP. Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor. J Immunother, 2000; 23:332–343.
3.
NolanKF, YunCO, AkamatsuY, et al.Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Clin Cancer Res, 1999; 5:3928–3941.
4.
BrentjensRJ, DavilaML, RiviereI, et al.CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med, 2013; 5:177ra138.
5.
TurtleCJ, HanafiLA, BergerC, et al.Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med, 2016; 8:355ra116.
6.
MaudeSL, FreyN, ShawPA, et al.Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 2014; 371:1507–1517.
7.
PorterDL, LevineBL, KalosM, et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med, 2011; 365:725–733.
8.
HartmannJ, Schussler-LenzM, BondanzaA, et al.Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med, 2017; 9:1183–1197.
9.
KershawMH, WestwoodJA, ParkerLL, et al.A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res, 2006; 12:6106–6115.
10.
ParkJR, DigiustoDL, SlovakM, et al.Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther, 2007; 15:825–833.
11.
TillBG, JensenMC, WangJ, et al.CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood, 2012; 119:3940–3950.
12.
LamersCH, SleijferS, van SteenbergenS, et al.Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther, 2013; 21:904–912.
13.
JunghansRP. The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective. Cancer Gene Ther, 2017; 24:89–99.
14.
KershawMH, WestwoodJA, DarcyPK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer, 2013; 13:525–541.
15.
DottiG, GottschalkS, SavoldoB, et al.Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev, 2014; 257:107–126.
16.
GrossG, GorochovG, WaksT, et al.Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc, 1989; 21:127–130.
17.
GrossG, WaksT, EshharZ. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A, 1989; 86:10024–10028.
18.
SadelainM, BrentjensR, RiviereI. The basic principles of chimeric antigen receptor design. Cancer Discov, 2013; 3:388–398.
19.
BrentjensRJ, RiviereI, ParkJH, et al.Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 2011; 118:4817–4828.
20.
EmtagePC, LoAS, GomesEM, et al.Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res, 2008; 14:8112–8122.
21.
ZhongXS, MatsushitaM, PlotkinJ, et al.Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther, 2010; 18:413–420.
22.
LiuX, ZhangN, ShiH. Driving better and safer HER2-specific CARs for cancer therapy. Oncotarget, 2017; 8:62730–62741.
KamedaT, YasuiW, YoshidaK, et al.Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res, 1990; 50:8002–8009.
25.
SlamonDJ, GodolphinW, JonesLA, et al.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 1989; 244:707–712.
26.
SeidenfeldJ, SamsomDJ, RothenbergBM, et al.HER2 testing to manage patients with breast cancer or other solid tumors. Evid Rep Technol Assess (Full Rep), 2008; 1–362.
27.
ZhaoY, WangQJ, YangS, et al.A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol, 2009; 183:5563–5574.
28.
MoritzD, WelsW, MatternJ, et al.Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci U S A, 1994; 91:4318–4322.
29.
SmithC, OkernG, RehanS, et al.Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement. Clin Transl Immunol, 2015; 4:e31.
30.
AlmasbakH, AarvakT, VemuriMC. CAR T cell therapy: a game changer in cancer treatment. J Immunol Res, 2016; 2016:5474602.
31.
BarrettDM, SinghN, LiuX, et al.Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy, 2014; 16:619–630.
32.
LiY, KurlanderRJ. Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J Transl Med, 2010; 8:104.
